Arena Pharmaceuticals, Inc

Short Term Long Term Short Term Comparison Long Term Comparison
  • ARNA
  • 1d0.31%
  • 1w2.80%
  • 1m10.88%
  • 1y15.82%
ATH
  • ATH Price$462.50
  • ATH Date2000-08-31
  • % since ATH-85.88%
  • % to ATH608.05%
ATL
  • ATL Price$11.50
  • ATL Date2017-05-17
  • % from ATL468.00%
  • Last Low Price$11.5
  • Last Low Date2017-05-17
  • % From Last Low468.00%
IPO
  • IPO Price$0.00
  • % Current ROI USDN/A
  • ATH Price$462.50
  • % ROI ATH 402,173.91%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="ARNA"]

Key Data [addtoany]

Current price $65.32
Sector Healthcare
Industry Biotechnology
Today's High/Low $67.5/$65.21
Volume 454,602.00
Previous Close $65.12
52 Week High/Low $69.75/$32.95
Market Cap 3,701,161,728.00
P/E Ratio 6.775
Forward P/E 1 Yr. $0.00
Earnings Per Share(EPS) $-8.27
Annualized Dividend $0
$65.32
[addtoany]

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide.
Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn’s disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase I clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction is in Phase II clinical trial.
It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension.
The company has collaboration agreements with Second Genome, Inc.; United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; Eisai Inc.; and Aristea Therapeutics, Inc. for the development of RIST4721 for treatment of serious immune-mediated inflammatory diseases. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah.

Annual Data | Millions of US $ except per share data
Cash on hand
Receivables
Inventory
Pre-Paid Expenses
Other Current Assets
Total Current Assets
Property, Plant, And Equipment
Long-Term Investments
Goodwill And Intangible Assets
Other Long-Term Assets
Total Long-Term Assets
Total Assets
Total Current Liabilities
Long Term Debt
Other Non-Current Liabilities
Total Long Term Liabilities
Total Liabilities
Common Stock Net
Retained Earnings (Accumulated Deficit)
Comprehensive Income
Other Share Holders Equity
Share Holder Equity
Total Liabilities And Share Holders Equity